Naftopidil for the treatment of benign prostate hyperplasia: a systematic review

References

• Parsons JK, Bergstrom J, Silberstein J, et al. Prevalence and characteristics of lower urinary tract symptoms in men aged > or = 80 years. Urology 2008;72:318-21
   PubMed Web of Science ®Google Scholar
• Oelke M, Bachmann A, Descazeaud A, et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 2013;64:118-40
   PubMed Web of Science ®Google Scholar
• Andersson KE, Gratzke C. Pharmacology of alpha1-adrenoceptor antagonists in the lower urinary tract and central nervous system. Nat Clin Pract Urol 2007;4:368-78
   PubMedGoogle Scholar
• Murata S, Taniguchi T, Takahashi M, et al. Tissue selectivity of KMD-3213, an alpha(1)-adrenoreceptor antagonist, in human prostate and vasculature. J Urol 2000;164:578-83
   PubMed Web of Science ®Google Scholar
• Schwinn DA, Roehrborn CG. Alpha1-adrenoceptor subtypes and lower urinary tract symptoms. Int J Urol 2008;15:193-9
   PubMed Web of Science ®Google Scholar
• Nasu K, Moriyama N, Kawabe K, et al. Quantification and distribution of alpha 1-adrenoceptor subtype mRNAs in human prostate: comparison of benign hypertrophied tissue and non-hypertrophied tissue. Br J Pharmacol 1996;119:797-803
   PubMed Web of Science ®Google Scholar
• Guimaraes S, Moura D. Vascular adrenoceptors: an update. Pharmacol Rev 2001;53:319-56
   PubMed Web of Science ®Google Scholar
• Schilit S, Benzeroual KE. Silodosin: a selective alpha1A-adrenergic receptor antagonist for the treatment of benign prostatic hyperplasia. Clin Ther 2009;31:2489-502
   PubMed Web of Science ®Google Scholar
• Nickel JC, Sander S, Moon TD. A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia. Int J Clin Pract 2008;62:1547-59
   PubMed Web of Science ®Google Scholar
• Farthing MJ, Alstead EM, Abrams SM, et al. Pharmacokinetics of naftopidil, a novel anti-hypertensive drug, in patients with hepatic dysfunction. Postgrad Med J 1994;70:363-6
   PubMed Web of Science ®Google Scholar
• Masumori N. Naftopidil for the treatment of urinary symptoms in patients with benign prostatic hyperplasia. Ther Clin Risk Manag 2011;7:227-38
   PubMed Web of Science ®Google Scholar
• Gotoh M, Kamihira O, Kinukawa T, et al. Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial. BJU Int 2005;96:581-6
   PubMed Web of Science ®Google Scholar
• Ikemoto I, Kiyota H, Ohishi Y, et al. Usefulness of tamsulosin hydrochloride and naftopidil in patients with urinary disturbances caused by benign prostatic hyperplasia: a comparative, randomized, two-drug crossover study. Int J Urol 2003;10:587-94
   PubMed Web of Science ®Google Scholar
• Masumori N, Hashimoto J, Itoh N, et al. Short-term efficacy and long-term compliance/treatment failure of the alpha1 blocker naftopidil for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Scand J Urol Nephrol 2007;41:422-9
   PubMed Web of Science ®Google Scholar
• Momose H, Hosokawa Y, Kishino T, et al. Crossover comparison study on the therapeutic effects of tamsulosin hydrochloride and naftopidil in lower urinary tract symptoms associated with benign prostatic hyperplasia. Drugs Today (Barc) 2007;43(Suppl A):1-10
   PubMedGoogle Scholar
• Nishino Y, Masue T, Miwa K, et al. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. BJU Int 2006;97:747-51, discussion 51
   PubMed Web of Science ®Google Scholar
• Ukimura O, Kanazawa M, Fujihara A, et al. Naftopidil versus tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia with special reference to the storage symptom: a prospective randomized controlled study. Int J Urol 2008;15:1049-54
   PubMed Web of Science ®Google Scholar
• Shirakawa T, Haraguchi T, Shigemura K, et al. Silodosin versus naftopidil in Japanese patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized multicenter study. Int J Urol 2013;20:903-10
   Google Scholar
• Yamaguchi K, Aoki Y, Yoshikawa T, et al. Silodosin versus naftopidil for the treatment of benign prostatic hyperplasia: a multicenter randomized trial. Int J Urol 2013;20:1234-8
   Google Scholar
• Yokoyama T, Hara R, Fukumoto K, et al. Effects of three types of alpha-1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia. Int J Urol 2011;18:225-30
   PubMed Web of Science ®Google Scholar
• Yamanishi T, Yasuda K, Kamai T, et al. Single-blind, randomized controlled study of the clinical and urodynamic effects of an alpha-blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia. Int J Urol 2004;11:501-9
   PubMed Web of Science ®Google Scholar
• Yokoyama T, Kumon H, Nasu Y, et al. Comparison of 25 and 75 mg/day naftopidil for lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective, randomized controlled study. Int J Urol 2006;13:932-8
   PubMed Web of Science ®Google Scholar
• Tsuritani S, Nozaki T, Okumura A, et al. A prospective, randomized, controlled, multicenter study of naftopidil for treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia: 75 mg once daily in the evening compared to 25 mg thrice daily. Urol Int 2010;85:80-7
   PubMed Web of Science ®Google Scholar
• Maruyama O, Kawachi Y, Hanazawa K, et al. Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: a prospective randomized controlled study. Int J Urol 2006;13:1280-5
   PubMed Web of Science ®Google Scholar
• Yokoyama T, Uematsu K, Watanabe T, et al. Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: a prospective randomized controlled study. Scand J Urol Nephrol 2009;43:307-14
   PubMed Web of Science ®Google Scholar
• Funahashi Y, Hattori R, Matsukawa Y, et al. Clinical efficacy of a loading dose of naftopidil for patients with benign prostate hyperplasia. World J Urol 2010;29:225-31
   PubMed Web of Science ®Google Scholar
• Yamaguchi S, Osanai H, Numata A, et al. alpha1D/A-adrenoceptor antagonist naftopidil for the male lower urinary tract symptoms associated with benign prostatic hyperplasia: efficacy of dose increase therapy. Int J Urol 2013;20:513-9
   Google Scholar
• Mizusawa T, Hara N, Obara K, et al. Clinical feature of men who benefit from dose escalation of naftopidil for lower urinary tract symptoms: a prospective study. Adv Urol 2011;2011:804583
   PubMedGoogle Scholar
• Oh-oka H. Usefulness of naftopidil for dysuria in benign prostatic hyperplasia and its optimal dose – comparison between 75 and 50 mg. Urol Int 2009;82:136-42
   PubMed Web of Science ®Google Scholar
• Masumori N, Tsukamoto T, Iwasawa A, et al. Ejaculatory disorders caused by alpha-1 blockers for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: comparison of naftopidil and tamsulosin in a randomized multicenter study. Urol Int 2009;83:49-54
   PubMed Web of Science ®Google Scholar
• Kojima Y, Sasaki S, Kubota Y, et al. Expression of alpha1-adrenoceptor subtype mRNA as a predictor of the efficacy of subtype selective alpha1-adrenoceptor antagonists in the management of benign prostatic hyperplasia. J Urol 2008;179:1040-6
   PubMed Web of Science ®Google Scholar
• Oh-oka H. Effect of naftopidil on nocturia after failure of tamsulosin. Urology 2008;72:1051-5
   PubMed Web of Science ®Google Scholar
• Kawachi Y, Sakurai T, Sugimura S, et al. Long-term treatment and prognostic factors of alpha 1-blockers for lower urinary tract symptoms associated with benign prostatic hyperplasia: a pilot study comparing naftopidil and tamsulosin hydrochloride. Scand J Urol Nephrol 2010;44:38-45
   PubMed Web of Science ®Google Scholar
• Athanasopoulos A, Gyftopoulos K, Giannitsas K, et al. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol 2003;169:2253-6
   PubMed Web of Science ®Google Scholar
• Lee JY, Kim HW, Lee SJ, et al. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int 2004;94:817-20
   PubMed Web of Science ®Google Scholar
• Greco KA, McVary KT. The role of combination medical therapy in benign prostatic hyperplasia. Int J Impot Res 2008;20(Suppl 3):S33-43
   PubMedGoogle Scholar
• Takahashi S, Tajima A, Matsushima H, et al. Clinical efficacy of an alpha1A/D-adrenoceptor blocker (naftopidil) on overactive bladder symptoms in patients with benign prostatic hyperplasia. Int J Urol 2006;13:15-20
   PubMed Web of Science ®Google Scholar
• Yokoyama O, Aoki Y, Tsujimura A, et al. alpha(1)-adrenoceptor blocker naftopidil improves sleep disturbance with reduction in nocturnal urine volume. World J Urol 2010;29:233-8
   PubMed Web of Science ®Google Scholar
• Awa Y, Suzuki H, Hamano S, et al. Clinical effect of alpha 1D/A adrenoceptor inhibitor naftopidil on benign prostatic hyperplasia: an international prostate symptom score and King's Health Questionnaire assessment. Int J Urol 2008;15:709-15
   PubMed Web of Science ®Google Scholar
• Komiya A, Suzuki H, Awa Y, et al. Clinical effect of naftopidil on the quality of life of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a prospective study. Int J Urol 2010;17:555-62
   PubMed Web of Science ®Google Scholar
• Buck AC. Phytotherapy for the prostate. Br J Urol 1996;78:325-36
   PubMedGoogle Scholar
• Chang DF, Campbell JR. Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg 2005;31:664-73
   PubMed Web of Science ®Google Scholar
• Oshika T, Ohashi Y, Inamura M, et al. Incidence of intraoperative floppy iris syndrome in patients on either systemic or topical alpha(1)-adrenoceptor antagonist. Am J Ophthalmol 2007;143:150-1
   PubMed Web of Science ®Google Scholar